Advanced search
Publication Cover
International Journal of Neuroscience Volume 129, 2019 - Issue 2
Submit an article Journal homepage
1,591
Views
83
CrossRef citations to date
0
Altmetric
Original Articles

Sativex® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial

Jolana MarkovàNeurology Department, Thomayer's Hospital, Praha, Czechia; Correspondence[email protected]
View further author information
,
Ute EssnerO. Meany Consultancy GmbH, Hamburg, Germany; View further author information
,
Bülent AkmazMarket Access Manager, Almirall Hermal GmbH, Reinbek, Germany; View further author information
,
Marcella MarinelliClinical Statistics, Almirall S.A., Barcelona, Spain; View further author information
,
Christiane TrompkeInternational Clinical Trial Managers, Almirall Hermal GmbH, Reinbek, Germany; View further author information
,
Arnd LentschatInternational Clinical Trial Managers, Almirall Hermal GmbH, Reinbek, Germany; View further author information
&
Carlos VilaNeurology Medical Manager, Global Medical Affairs, Almirall S.A., Barcelona, SpainView further author information
 show all
Pages 119-128 | Received 20 Feb 2018, Accepted 21 May 2018, Published online: 13 Sep 2018

References

  • Rizzo MA, Hadjimichael OC, Preiningerova J, et al. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler. 2004;10:589–595.
  • de Sa JC, Airas L, Bartholome E, et al. Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice. Ther Adv Neurol Disord. 2011;4:139–168.
  • Kister I, Bacon TE, Chamot E, et al. Natural history of multiple sclerosis symptoms. Int J MS Care. 2013;15:146–158.
  • Gold R, Oreja-Guevara C. Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity guidelines. Expert Rev Neurother. 2013;13(12Suppl):55–59.
  • Milinis K, Tennant A, Young CA, et al. Spasticity in multiple sclerosis: associations with impairments and overall quality of life. Mult Scler Relat Disord. 2016;5:34–39.
  • Svensson J, Borg S, Nilsson P. Costs and quality of life in multiple sclerosis patients with spasticity. Acta Neurol Scand. 2014;129:13–20.
  • Flachenecker P, Henze T, Zettl UK. Spasticity in patients with multiple sclerosis-clinical characteristics, treatment and quality of life. Acta Neurol Scand. 2014;129:154–162.
  • Arroyo R, Massana M, Vila C. Correlation between spasticity and quality of life in patients with multiple sclerosis: the CANDLE study. Int J Neurosci. 2013;123:850–858.
  • Oreja-Guevara C, Montalban X, de Andrés C, et al.; Grupo de Enfermedades Desmielinizantes de la Sociedad Española de Neurología [Consensus document on spasticity in patients with multiple sclerosis. Grupo de Enfermedades Desmielinizantes de la Sociedad Española de Neurología]. Rev Neurol. 2013; 57(8):359–373.
  • Beard S, Hunn A, Wight J. Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol Assess. 2003;7(40):iii, ix–111.
  • Chang E, Ghosh N, Yanni D, et al. A review of spasticity treatments: pharmacological and interventional approaches. Crit Rev Phys Rehabil Med. 2013;25:11–22.
  • Pozzilli C. Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice. Expert Rev Neurother. 2013;13(12Suppl):49–54.
  • Otero-Romero S, Sastre-Garriga J, Comi G, et al. Pharmacological management of spasticity in multiple sclerosis: systematic review and consensus paper. Mult Scler. 2016;22:1386–1396.
  • Wade DT, Makela P, Robson P, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004;10:434–441.
  • Collin C, Davies P, Mutiboko IK, et al. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol. 2007;14:290–296.
  • Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®)) , as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011;18:1122–1131.
  • Flachenecker P, Henze T, Zettl UK. Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice-results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity. Eur Neurol. 2014;71:271–279.
  • Patti F, Messina S, Solaro C, et al. Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. J Neurol Neurosurg Psychiatry. 2016;87:944–951.
  • eMC Sativex Oromucosal Spray SPC. 2015. [cited 2017 Sep 22] Available at: https://www.medicines.org.uk/emc/history/23262
  • Farrar JT, Troxel AB, Stott C, et al. Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. Clin Ther. 2008;30:974–985.
  • Collin C, Ehler E, Waberzinek G, et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res. 2010;32(5):451–459.
  • Wininger M, Craelius W, Settle J, et al. Biomechanical analysis of spasticity treatment in patients with multiple sclerosis. Ther Adv Neurol Disord. 2015;8(5):203–211.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.